ES2187820T3 - Formulaciones farmaceuticas de factor de liberacion de la corticotrop ina que tiene una estabilidad en su forma liquida. - Google Patents

Formulaciones farmaceuticas de factor de liberacion de la corticotrop ina que tiene una estabilidad en su forma liquida.

Info

Publication number
ES2187820T3
ES2187820T3 ES97942511T ES97942511T ES2187820T3 ES 2187820 T3 ES2187820 T3 ES 2187820T3 ES 97942511 T ES97942511 T ES 97942511T ES 97942511 T ES97942511 T ES 97942511T ES 2187820 T3 ES2187820 T3 ES 2187820T3
Authority
ES
Spain
Prior art keywords
formulations
crf
present
liquid form
pharmaceutical formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97942511T
Other languages
English (en)
Inventor
Bert Ho
Behzad Khosrovi
Pamela G Hirtzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurobiological Technologies Inc
Original Assignee
Neurobiological Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurobiological Technologies Inc filed Critical Neurobiological Technologies Inc
Application granted granted Critical
Publication of ES2187820T3 publication Critical patent/ES2187820T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVAS FORMULACIONES FARMACEUTICAS DEL FACTOR DE LIBERACION DE LA CORTICOTROPINA (FLC) QUE TIENEN UNA MEJOR ESTABILIDAD DURANTE EL ALMACENAMIENTO EN FORMA DE LIQUIDOS DURANTE UN LARGO PERIODO, QUE CONSERVAN SENSIBLEMENTE SU ACTIVIDAD FARMACEUTICA DURANTE DICHO PERIODO Y/O QUE SON COMPATIBLES DESDE EL PUNTO DE VISTA FISIOLOGICO. LAS FORMULACIONES DE LA PRESENTE INVENCION COMPRENDEN: (A) UNA CONCENTRACION DE FLC EFICIENTE DESDE EL PUNTO DE VISTA FARMACEUTICO; (B) UN TAMPON QUE PERMITE MANTENER EL PH DE LA FORMULACION EN FORMA LIQUIDA ENTRE APROXIMADAMENTE 2,0 Y 5,0 O ENTRE UNOS 6,0 Y 9,0 Y (C) UN ALCOHOL COMO POR EJEMPLO EL MANITOL, EL SORBITOL, EL METANOL, EL GLICEROL O UN ALCOHOL SIMILAR. OTROS ASPECTOS DE ESTA INVENCION SE REFIEREN A LA UNION A ESTAS FORMULACIONES DE OTROS VARIOS COMPUESTOS, Y CUYA FINALIDAD CONSISTE EN REBAJAR LA VELOCIDAD DE DEGRADACION DEL PEPTIDO FLC O INCREMENTAR SU SOLUBILIDAD EN UNA SOLUCION. ESTA INVENCION SE REFIERE TAMBIEN A UNOS PROCEDIMIENTOS DE PREPARACION DE NUEVAS FORMULACIONES FARMACEUTICAS A BASE DE FLC O DE USO DE DICHAS FORMULACIONES PARA REDUCIR LA INFLAMACION Y EL EDEMA EN LOS MAMIFEROS.
ES97942511T 1996-09-20 1997-09-17 Formulaciones farmaceuticas de factor de liberacion de la corticotrop ina que tiene una estabilidad en su forma liquida. Expired - Lifetime ES2187820T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/717,306 US5780431A (en) 1996-09-20 1996-09-20 Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form

Publications (1)

Publication Number Publication Date
ES2187820T3 true ES2187820T3 (es) 2003-06-16

Family

ID=24881496

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97942511T Expired - Lifetime ES2187820T3 (es) 1996-09-20 1997-09-17 Formulaciones farmaceuticas de factor de liberacion de la corticotrop ina que tiene una estabilidad en su forma liquida.

Country Status (9)

Country Link
US (1) US5780431A (es)
EP (1) EP0929314B1 (es)
JP (1) JP4147329B2 (es)
AT (1) ATE228005T1 (es)
AU (1) AU4419497A (es)
CA (1) CA2266666C (es)
DE (1) DE69717293T2 (es)
ES (1) ES2187820T3 (es)
WO (1) WO1998011912A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU768277B2 (en) * 1998-05-15 2003-12-04 Warner-Lambert Company Llc Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
US6599883B1 (en) 1998-10-30 2003-07-29 Nastech Pharmaceutical Company, Inc. Nasal delivery of xylitol
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
WO2000066155A1 (en) 1999-04-30 2000-11-09 La Jolla Institute For Allergy And Immunology Methods for preventing reactivation of latent virus and controlling virus replication
DE19930676B4 (de) * 1999-07-02 2006-01-19 Sanofi-Aventis Deutschland Gmbh Verfahren zur Stabilisierung von Insulin, Insulinderivaten und/oder deren Vorläufer in komplexen Mischungen bei deren Lagerung in wäßrigen Lösungsmitteln
DE10085144T1 (de) * 1999-10-28 2003-04-24 Inst Neftechimicheskogo Sintez Polypeptidkomposition
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
CN100411683C (zh) 2002-05-21 2008-08-20 阿斯比奥制药株式会社 含有生长素释放肽的药物组合物
CL2004000698A1 (es) * 2003-03-31 2005-05-20 Alza Corp Comosicion farmaceutica no acuosa que comprende al menos un ingrediente activo y un vehiculo de fase unica que contiene al menos un polimero y al menos un solvente, siendo el vehiculo miscible en agua; procedimiento para su preparacion; dispositivo d
TR201816556T4 (tr) 2004-04-02 2018-11-21 Swedish Orphan Biovitrum Ab Publ Il-1ra agregasyonunun azaltilmasina yöneli̇k yöntemler
WO2006022301A1 (ja) * 2004-08-24 2006-03-02 Daiichi Asubio Pharma Co., Ltd. 生理活性ペプチド液状製剤
EP1920779A4 (en) * 2005-08-12 2010-03-10 Astellas Pharma Inc YW753 PREPARATION STABILIZATION TECHNIQUE
US20100249027A1 (en) * 2007-05-25 2010-09-30 William Henry Crf conjugates with extended half-lives
WO2008156719A1 (en) * 2007-06-14 2008-12-24 Neutron Ltd. Steroid-sparing methods of treating brain edema
KR20110021820A (ko) * 2008-04-30 2011-03-04 뉴트론 로우 암 치료를 위한 부신 피질 자극 호르몬 방출 인자의 사용 방법
US20130213393A1 (en) 2009-12-22 2013-08-22 Evoke Pharma, Inc. Nasal formulations of metoclopramide
CA3155873C (en) * 2008-12-22 2024-03-19 Evoke Pharma, Inc. Nasal formulations of metoclopramide
US11517545B2 (en) 2016-12-15 2022-12-06 Evoke Pharma, Inc. Treatment of moderate and severe gastroparesis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236901A (en) * 1988-04-20 1993-08-17 Research Corporation Technologies, Inc. Treatment for irritable bowel syndrome
US5177060A (en) * 1990-01-09 1993-01-05 Regents Of The University Of California Anti-inflammatory peptides and treatment to inhibit vascular leakage in injured tissues
AU8131694A (en) * 1993-11-02 1995-05-23 Neurobiological Technologies, Inc. Treatment for rheumatoid arthritis

Also Published As

Publication number Publication date
JP2001500876A (ja) 2001-01-23
CA2266666C (en) 2003-11-25
JP4147329B2 (ja) 2008-09-10
DE69717293D1 (de) 2003-01-02
ATE228005T1 (de) 2002-12-15
WO1998011912A1 (en) 1998-03-26
EP0929314A1 (en) 1999-07-21
AU4419497A (en) 1998-04-14
DE69717293T2 (de) 2003-09-04
EP0929314B1 (en) 2002-11-20
CA2266666A1 (en) 1998-03-26
US5780431A (en) 1998-07-14

Similar Documents

Publication Publication Date Title
ES2187820T3 (es) Formulaciones farmaceuticas de factor de liberacion de la corticotrop ina que tiene una estabilidad en su forma liquida.
NO934355L (no) Proteinformulering omfattende veksthormon
EA200000629A1 (ru) Стабилизированные растворы терипаратида
MX9305146A (es) Conjugado de interferon, procedimiento para su preracion y composicion farmaceutica que lo contienen.
ATE244015T1 (de) Formulierungen fuer faktor ix
FI971776A (fi) Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi
PA8575701A1 (es) Preparaciones acidas de insulina con estabilidad mejorada
ES2157307T3 (es) Composicion topica que contiene un antagonista de sustancia p.
KR850007559A (ko) 조절 펩타이드의 삽입식 제형
SV1997000049A (es) Conjugados de interferones ref. 12614 sv
DK0999853T3 (da) Stabiliseret antostofformulering
DE69729786D1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
ES2051678T1 (es) Derivados de 5-oxo-l-prolina y uso farmaceutico de los mismos.
ATE221780T1 (de) Fenbendazolformulierungen
DK0666739T3 (da) Intravenøs opløsning som formindsker protein- og vandtab fra kroppen
DK1212039T3 (da) Sammensætning til inhalation omfattende delta-9-tetrahydrocannabinol i et semivandigt oplösningsmiddel
DE69531736D1 (de) Oxytetracyclin enthaltendes arzneimittel mit verzögerter wirksoffabgabe
JPS55160712A (en) Emulsified cosmetic composition
ES2051709T3 (es) Un procedimiento para la preparacion de una composicion farmaceutica para uso parenteral que contiene calcitonina como el ingrediente activo.
EA200200415A1 (ru) Композиция фармацевтического носителя
HUP0004362A2 (hu) Karbamazepint vagy származékait tartalmazó parenterális készítmények
TW328049B (en) Penciclover/propylene glycol composition
KR930012023A (ko) 환원된 형태의 비글리코실화 재조합 인체 il2의 안정화된 제약 조성물 및 그의 제조방법
CO4370014A1 (es) Soluciones inyectables estables de diritromicina
RU97103681A (ru) Мазь для лечения заболеваний, вызываемых вирусом герпеса